September 12, 2017
Zynerba Pharmaceuticals (NASDAQ:ZYNE) just released its September investor presentation, and we think it's worth taking a look! Scroll through the slides below for an in-depth look at what's going on at Zynerba.
Read more articles tagged:
Facts You Need to Know About Cannabis
October 15, 2020
5 Products Every Vegan Needs When Traveling
October 6, 2020
Quintessential Californian Edible Recipes to Make...
October 2, 2020
How Does Smoking Cannabis Contribute to Your Socia...
April 8, 2020
Can You Strengthen Your Immune System With Cannabi...
50 Blue Chip Stocks Worth Less than Half as Much a...
September 19, 2018
5 of Today's Biggest Marijuana Stock Losers -...
September 10, 2018
5 of Today's Biggest Marijuana Stock Gainers -...
September 5, 2018
September 4, 2018
Roth Capital Upgraded Zynerba to a Buy Rating
August 16, 2017
Trading Marijuana Stocks With Ally Invest
August 7, 2017
7 Things To Know About Zynerba's Pipeline & Q2 Earnings Release
August 2, 2017
Zynerba Reaches Target Enrollment in Phase 2 Fragile X Study
June 8, 2017
Zynerba to Present at Jefferies Healthcare Conference
June 1, 2017
Insider Buying by CEO & CFO at Zynerba Pharmaceuticals
May 19, 2017